New York Life Investment Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.33M | Sell |
10,589
-403
| -4% | -$50.7K | 0.01% | 594 |
|
|
2025
Q1 | $1.22M | Sell |
10,992
-2
| -0% | -$221 | 0.01% | 620 |
|
|
2024
Q4 | $1.5M | Sell |
10,994
-1,688
| -13% | -$230K | 0.01% | 594 |
|
|
2024
Q3 | $1.46M | Buy |
12,682
+437
| +4% | +$50.4K | 0.01% | 627 |
|
|
2024
Q2 | $1.69M | Buy |
12,245
+1,330
| +12% | +$183K | 0.02% | 593 |
|
|
2024
Q1 | $1.51M | Sell |
10,915
-268
| -2% | -$37K | 0.02% | 600 |
|
|
2023
Q4 | $1.47M | Buy |
11,183
+315
| +3% | +$41.5K | 0.02% | 591 |
|
|
2023
Q3 | $1.22M | Buy |
10,868
+5,435
| +100% | +$611K | 0.01% | 591 |
|
|
2023
Q2 | $512K | Buy |
+5,433
| New | +$512K | 0.01% | 702 |
|